CD4 and neoplasm: Treatment with the anti‐PD‐L1 inhibitor showed a marked increase in CD8+ and CD4+ T‐cell infiltration inside the tumor, indicating an immunogenic microenvironment (Fig. 4A,E, Fig. S6A,D).